Arcellx, Inc. (ACLX)

$52.82

-1.62

(-2.98%)

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Arcellx, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 19.8%

Performance

  • $52.54
    $54.94
    $52.82
    downward going graph

    0.53%

    Downside

    Day's Volatility :4.37%

    Upside

    3.86%

    downward going graph
  • $30.74
    $75.10
    $52.82
    downward going graph

    41.8%

    Downside

    52 Weeks Volatility :59.07%

    Upside

    29.67%

    downward going graph

Returns

PeriodArcellx, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-8.26%
2.0%
0.0%
6 Months
68.18%
11.7%
0.0%
1 Year
32.78%
5.8%
1.3%
3 Years
224.05%
14.2%
-22.1%

Highlights

Market Capitalization
2.8B
Book Value
$9.28
Earnings Per Share (EPS)
-1.47
Wall Street Target Price
80.31
Profit Margin
-64.08%
Operating Margin TTM
23.75%
Return On Assets TTM
-9.86%
Return On Equity TTM
-20.48%
Revenue TTM
110.3M
Revenue Per Share TTM
2.3
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-87.8M
Diluted Eps TTM
-1.47
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.94
EPS Estimate Next Year
-2.01
EPS Estimate Current Quarter
-0.61
EPS Estimate Next Quarter
-0.59

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Arcellx, Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
16
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.04%

Current $52.82
Target $80.31

Technicals Summary

Sell

Neutral

Buy

Arcellx, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcellx, Inc.
Arcellx, Inc.
-20.91%
68.18%
32.78%
224.05%
224.05%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
11.53%
21.99%
86.62%
131.89%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcellx, Inc.
Arcellx, Inc.
NA
NA
NA
-1.94
-0.2
-0.1
NA
9.28
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcellx, Inc.
Arcellx, Inc.
Buy
$2.8B
224.05%
NA
-64.08%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
131.89%
28.81
36.68%

Institutional Holdings

  • Perceptive Advisors LLC

    8.61%
  • FMR Inc

    8.29%
  • NEA Management Company, LLC

    7.09%
  • Paradigm Biocapital Advisors LP

    6.93%
  • SR ONE CAPITAL MANAGEMENT, LP

    5.96%
  • BlackRock Inc

    5.72%

Corporate Announcements

  • Arcellx, Inc. Earnings

    Arcellx, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.

Organization
Arcellx, Inc.
Employees
130
CEO
Mr. Rami Elghandour
Industry
Healthcare

FAQs